tetano
Editor, Senior Moderator
Neurol Neuroimmunol Neuroinflamm
. 2022 May 6;9(4):e1178.
doi: 10.1212/NXI.0000000000001178. Print 2022 Jul.
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
Virginia Palomares Cabeza[SUP] 1 [/SUP], Laura Y L Kummer[SUP] 2 [/SUP], Luuk Wieske[SUP] 1 [/SUP], Ruth R Hagen[SUP] 1 [/SUP], Mariel Duurland[SUP] 1 [/SUP], Veronique A L Konijn[SUP] 1 [/SUP], Koos P J van Dam[SUP] 1 [/SUP], Eileen W Stalman[SUP] 1 [/SUP], Carolien E van de Sandt[SUP] 1 [/SUP], Laura Boekel[SUP] 1 [/SUP], Niels J M Verstegen[SUP] 1 [/SUP], Maurice Steenhuis[SUP] 1 [/SUP], Theo Rispens[SUP] 1 [/SUP], Sander W Tas[SUP] 1 [/SUP], Gertjan Wolbink[SUP] 1 [/SUP], Joep Killestein[SUP] 1 [/SUP], Taco W Kuijpers[SUP] 1 [/SUP], S Marieke van Ham[SUP] 1 [/SUP], Filip Eftimov[SUP] 1 [/SUP], Anja Ten Brinke[SUP] 1 [/SUP], Zoé L E van Kempen[SUP] 1 [/SUP], Target-to-B! (T2B!) SARS-CoV-2 study group
Affiliations
Abstract
Objectives: To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
Methods: This is a substudy of a prospective multicenter study on SARS-CoV-2 vaccination in patients with immune-mediated diseases. Patients with MS treated with ocrelizumab, fingolimod, and no disease-modifying therapies and healthy controls were included. The number of interferon (IFN)-γ secreting SARS-CoV-2-specific T cells at multiple time points before and after 3 SARS-CoV-2 vaccinations were evaluated.
Results: In ocrelizumab-treated patients (N = 24), IFN-γ-producing SARS-CoV-2-specific T-cell responses were induced after 2 vaccinations with median levels comparable to healthy controls (N = 12) and patients with MS without disease-modifying therapies (N = 10). A third vaccination in ocrelizumab-treated patients (N = 8) boosted T-cell responses that had declined after the second vaccination, but did not lead to higher overall T-cell responses as compared to immediately after a second vaccination. In fingolimod-treated patients, no SARS-CoV-2-specific T cells were detected after second (N = 12) and third (N = 9) vaccinations.
Discussion: In ocrelizumab-treated patients with MS, a third SARS-CoV-2 vaccination had no additive effect on the maximal T-cell response but did induce a boost response. In fingolimod-treated patients, no T-cell responses could be detected following both a second and third SARS-CoV-2 vaccination.
. 2022 May 6;9(4):e1178.
doi: 10.1212/NXI.0000000000001178. Print 2022 Jul.
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
Virginia Palomares Cabeza[SUP] 1 [/SUP], Laura Y L Kummer[SUP] 2 [/SUP], Luuk Wieske[SUP] 1 [/SUP], Ruth R Hagen[SUP] 1 [/SUP], Mariel Duurland[SUP] 1 [/SUP], Veronique A L Konijn[SUP] 1 [/SUP], Koos P J van Dam[SUP] 1 [/SUP], Eileen W Stalman[SUP] 1 [/SUP], Carolien E van de Sandt[SUP] 1 [/SUP], Laura Boekel[SUP] 1 [/SUP], Niels J M Verstegen[SUP] 1 [/SUP], Maurice Steenhuis[SUP] 1 [/SUP], Theo Rispens[SUP] 1 [/SUP], Sander W Tas[SUP] 1 [/SUP], Gertjan Wolbink[SUP] 1 [/SUP], Joep Killestein[SUP] 1 [/SUP], Taco W Kuijpers[SUP] 1 [/SUP], S Marieke van Ham[SUP] 1 [/SUP], Filip Eftimov[SUP] 1 [/SUP], Anja Ten Brinke[SUP] 1 [/SUP], Zoé L E van Kempen[SUP] 1 [/SUP], Target-to-B! (T2B!) SARS-CoV-2 study group
Affiliations
- PMID: 35523569
- DOI: 10.1212/NXI.0000000000001178
Abstract
Objectives: To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
Methods: This is a substudy of a prospective multicenter study on SARS-CoV-2 vaccination in patients with immune-mediated diseases. Patients with MS treated with ocrelizumab, fingolimod, and no disease-modifying therapies and healthy controls were included. The number of interferon (IFN)-γ secreting SARS-CoV-2-specific T cells at multiple time points before and after 3 SARS-CoV-2 vaccinations were evaluated.
Results: In ocrelizumab-treated patients (N = 24), IFN-γ-producing SARS-CoV-2-specific T-cell responses were induced after 2 vaccinations with median levels comparable to healthy controls (N = 12) and patients with MS without disease-modifying therapies (N = 10). A third vaccination in ocrelizumab-treated patients (N = 8) boosted T-cell responses that had declined after the second vaccination, but did not lead to higher overall T-cell responses as compared to immediately after a second vaccination. In fingolimod-treated patients, no SARS-CoV-2-specific T cells were detected after second (N = 12) and third (N = 9) vaccinations.
Discussion: In ocrelizumab-treated patients with MS, a third SARS-CoV-2 vaccination had no additive effect on the maximal T-cell response but did induce a boost response. In fingolimod-treated patients, no T-cell responses could be detected following both a second and third SARS-CoV-2 vaccination.